Head of Innovation & New Product Development
About the job
- Bachelor's degree in Business, Marketing, Science, Engineering, Product Development, or a related field.
- 10+ years of progressive experience in innovation, new product development, brand management, portfolio strategy, commercialization, or related disciplines.
- A proven track record of identifying, developing, and launching successful consumer products.
- Experience leading innovation pipelines and managing cross-functional commercialization efforts.
- Demonstrated success operating within a Stage-Gate or similar innovation framework.
- Experience building and leading high-performing teams.
- Successful completion of background and reference checks.
- Develop and execute the innovation strategy aligned with Canopy Growth's growth ambitions and portfolio priorities.
- Build and manage a multi-year innovation pipeline across core, adjacent, and transformational opportunities.
- Identify new product, format, occasion, and category opportunities that drive sustainable growth.
- Partner with Brand and Portfolio Strategy to ensure innovation investments support portfolio objectives and long-term brand growth.
- Balance short-term commercial opportunities with longer-term strategic growth platforms.
- Champion a consumer-first approach to innovation across the organization.
- Partner with Strategic Insights to identify unmet consumer needs, emerging trends, changing behaviors, and white space opportunities.
- Ensure innovation concepts are grounded in consumer validation and supported by robust insights and analytics.
- Translate insights into actionable innovation strategies, concepts, and growth platforms.
- Embed consumer learning throughout the innovation lifecycle from ideation through commercialization.
- Lead the end-to-end new product development process from concept creation through market launch.
- Oversee concept screening, feasibility assessment, business case development, product development, and launch readiness.
- Collaborate with Product Development, Operations, Regulatory, Supply Chain, Commercial, and Marketing teams to deliver successful innovation launches.
- Ensure innovations provide meaningful consumer benefits and create sustainable competitive differentiation.
- Monitor post-launch performance and drive continuous improvement of innovation outcomes.
- Identify and develop scalable platform technologies and innovation capabilities across brands, product categories, and business units.
- Evaluate emerging technologies, formulations, delivery systems, ingredients, and product formats that enhance consumer experiences and create competitive advantage.
- Lead assessments of external partnerships, licensing opportunities, and innovation ecosystems that expand organizational capabilities.
- Develop future-focused innovation roadmaps that support long-term growth and category leadership.
- Drive exploration of adjacent opportunities informed by evolving consumer needs and market trends.
- Own and lead Canopy Growth's Stage-Gate innovation process.
- Establish governance, milestones, decision criteria, and accountability across innovation initiatives.
- Lead cross-functional innovation reviews and portfolio prioritization discussions.
- Ensure innovation resources are allocated to the highest-value opportunities.
- Continuously improve innovation processes, tools, and ways of working to increase effectiveness and speed-to-market.
- Align stakeholders around innovation priorities and growth opportunities.
- Influence executive decision-making through fact-based recommendations and compelling business cases.
- Foster collaboration across functions to accelerate innovation and improve execution.
- Build, lead, and develop a high-performing Innovation and New Product Development team.
- Create a culture of curiosity, experimentation, accountability, and consumer focus.
- Coach and develop team members to strengthen innovation, commercialization, and strategic thinking capabilities.
- Establish clear objectives, performance expectations, and development plans.
- Elevate innovation capabilities across the broader organization through best practices, education, and cross-functional engagement.
- Experience in cannabis, consumer packaged goods, beverage alcohol, food and beverage, wellness, or similarly regulated consumer industries.
About the company
Canopy Growth operates as a global cannabis company that develops, markets, and sells a wide range of cannabis products for medical and recreational use. Its product lineup includes dried flowers, oils, softgel capsules, and edibles, manufactured through advanced cultivation and extraction processes. The company distributes products via direct-to-consumer channels and retailer partnerships, and it extends its reach internationally into emerging markets. Core activities include rigorous research and development to improve formulations and create trusted brands, supported by a scalable production and distribution network. Canopy Growth differentiates itself through ongoing investment in R&D, a diversified brand portfolio, global expansion, and a commitment to sustainability and public health. Its overarching goal is to reshape how cannabis is perceived and used by expanding access to high-quality, science-backed products across the world.
Company Size
501-1,000
Company Stage
IPO
Headquarters
Smiths Falls, Canada
Founded
2014
Get referred to Canopy Growth
See people who can refer or advise you
Simplify's Take
What believers are saying
- Q1 fiscal 2027 revenue rose 13% to C$81.2 million, across all segments.
- UK medical launch began September 22, 2026, creating a new European revenue stream.
- Adjusted EBITDA loss narrowed 59% to C$3.2 million; management targets fiscal 2027 profitability.
What critics are saying
- Nasdaq delisting risk persists after 2026 reverse-split vote and sub-$1 share price.
- September 25, 2026 quorum failure delayed governance, signaling weak shareholder support and instability.
- Veterans Affairs reimbursement cuts pressure Canadian medical margins; dependence on one reimbursement channel is dangerous.
What makes Canopy Growth unique
- Canopy Growth leads Canadian medical cannabis through Spectrum, Abba Medix, Apollo, Canada House Clinics.
- EU GMP-certified Kincardine and Sankt Leon-Rot enable Canadian flower exports into Europe.
- MTL Cannabis integration strengthens cultivation, clinics, and premium brands across Canada and Germany.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Health Insurance
Dental Insurance
Paid Vacation
Remote Work Options
Growth & Insights and Company News
6 month growth
↑ 0%1 year growth
↑ 0%2 year growth
↓ -1%Canopy Growth appoints Sebastian Blöte as Country Manager for Germany. Published: September 28, 2026 at 9:32a.m. EDT SMITHS FALLS, Ontario-(BUSINESS WIRE)- Canopy Growth Corporation ("Canopy Growth", "our", "we" or the "Company") (TSX: WEED) (Nasdaq: CGC), a leading global company committed to bettering lives through cannabis, today announced the appointment of Sebastian Blöte as Country Manager for Germany, effective October 1, 2026. Mr. Blöte will lead Canopy Growth's commercial strategy in Germany, with responsibility for expanding sales and strengthening execution across the market, deepening connections with partners and healthcare professionals, and driving growth to fully capture the significant potential of the German medical cannabis market. The appointment of Mr. Blöte builds on the progress Canopy Growth has made over the past year to strengthen its international medical cannabis business, including enhancing its European Union Good Manufacturing Practice supply capabilities from its Canadian cultivation operations. "Over the last year, we have put the pieces in place to build a stronger international medical cannabis business, delivering double-digit sequential growth for the past three quarters," said Luc Mongeau, Chief Executive Officer, Canopy Growth. "We have strengthened our cultivation and supply capabilities, broadened our portfolio and sharpened our commercial focus. Bringing Sebastian into the business is the next step in that strategy, adding more experienced leadership on the ground as we look to accelerate growth and capture more of the opportunity we see in Germany and across Europe." Mr. Blöte brings more than a decade of commercial leadership in the European cannabis industry. He most recently served as European Sales Director, then Digital Sales Director, at a leading European medical cannabis company based in Germany, leading its Swiss market entry, and a product launch in Austria. Earlier in his career, Mr. Blöte co-founded and led a medical cannabis import and distribution company in Germany. "I'm excited to build deeper relationships with clinics, pharmacies and healthcare professionals to better understand what they need from us and translate that into stronger commercial execution," said Sebastian Blöte. "Germany has a large and evolving medical cannabis ecosystem and Canopy Growth has the portfolio, supply capabilities and infrastructure in place; the opportunity now is to build on that foundation and increase the pace at which we grow." About Canopy Growth Canopy Growth is a leading global company committed to bettering lives through cannabis. With a focus on cultivation excellence, quality, trust, innovation and disciplined execution, Canopy Growth is a consumer-centric company serving patients, consumers and partners alike. The Company's portfolio of owned and licensed brands, including Tweed, 7ACRES, DOJA, Deep Space, DeeLish, Claybourne, MTL Cannabis, Low Key by MTL and R'belle, as well as category-defining Storz & Bickel, delivers innovative cannabis products to consumers across Canada and beyond. It is also Canada's leading provider of medical cannabis services through Spectrum Therapeutics, Abba Medix, Apollo, and Canada House Clinics. The Company also holds an unconsolidated, non-controlling interest in Canopy USA, LLC, which provides exposure to the U.S. THC market. Guided by its commitment to leadership, excellence, trust and innovation, Canopy Growth is working to shape a future where the plant is trusted for its ability to better lives. View source version on businesswire.com: https://www.businesswire.com/news/home/20260928356246/en/ Media Contact:[email protected] Investor Contact:[email protected] Business Wire
Canopy Growth Corporation has appointed Sebastian Blöte as country manager for Germany, effective 1 October 2026. Blöte will lead the company's commercial strategy in Germany, focusing on expanding sales and strengthening partnerships with healthcare professionals in the medical cannabis market. Blöte brings over a decade of commercial leadership experience in the European cannabis industry. He previously served as European sales director and digital sales director at a leading European medical cannabis company, where he led market entries in Switzerland and Austria. Earlier, he co-founded a medical cannabis import and distribution company in Germany. The appointment follows Canopy Growth's recent efforts to strengthen its international medical cannabis business, which has delivered double-digit sequential growth for three consecutive quarters.
Canopy Growth is planning another reverse stock split less than two years after its previous one in December 2023. The cannabis company's shares have fallen roughly 80% since that split and are now trading below $1, risking delisting from major exchanges. The shareholder vote on the proposed reverse split is scheduled for 25 September. Major exchanges typically require companies to maintain share prices above $1 to remain listed. Despite the stock's struggles, Canopy Growth reported 13% sales growth across all divisions in the first quarter of fiscal 2027. The company's losses also decreased by 68% compared to the same period last year. Analysts note that reverse splits are rarely positive developments and usually indicate a company has limited options. The previous reverse split was followed by a nearly 50% decline before a brief rally.
Canopy Growth expands medical marijuana business into UK with four canadian-grown strains. Canopy Growth announced Tuesday that it is expanding its European medical marijuana business into the United Kingdom, with four Canadian-grown flower strains set to be distributed in the country. The products will be supplied to GROW Group U.K. Ltd., a British pharmaceutical company that imports, manufactures and distributes prescribed cannabis-based medicines across Europe. GROW Group will commercialize the strains in the U.K. under Canopy Growth's Spectrum Therapeutics medical brand. Canopy Growth said the launch marks the first introduction of its portfolio products into the U.K. market. "Expanding availability of our products into the UK is another step in growing our European medical cannabis business and broadening the international reach of our Canadian-grown flower," said Canopy Growth Chief Executive Officer Luc Mongeau. Mongeau said the company sees additional opportunities to expand in European medical markets as demand grows and Canopy increases its ability to supply products meeting European manufacturing standards. The expansion follows the August renewal of European Union Good Manufacturing Practice (EU GMP) certification for Canopy Growth's cultivation facility in Kincardine, Ontario. The certification allows marijuana grown at the facility to continue being supplied to medical markets across Europe. Canopy said in August that the Kincardine facility serves as a central part of its European supply chain, connecting Canadian-grown marijuana with European distribution operations through a second EU GMP-certified facility in Sankt Leon-Rot, Germany. The company has increasingly emphasized international medical marijuana markets as part of its broader business strategy. Canopy reported in August that international cannabis revenue increased 10% year-over-year during the first quarter of its 2027 fiscal year. The U.K. has allowed doctors to prescribe cannabis-based medicines under certain circumstances since 2018, with a growing private medical marijuana market developing in the years since.
Canopy Growth reported 13% year-over-year revenue growth to C$81.2 million for the first quarter of fiscal 2027, exceeding analyst estimates of C$58.89 million. The cannabis company's shares rose 5% following the announcement. The Smiths Falls, Ontario-based firm saw growth across all business segments. Cannabis net revenue increased 14% to C$65.1 million, with Canadian medical cannabis up 22% to C$25.8 million and adult-use revenue rising 10% to C$29.7 million. International cannabis revenue grew 10% to C$9.6 million. Adjusted gross margin improved to 31% from 25% year-over-year, whilst adjusted EBITDA loss narrowed 59% to C$3.2 million. Net loss decreased 68% year-over-year.